Ghrelin Decreases Insulin Sensitivity

Ghrelin administration increases appetite and, in rodents, induces weight gain. The aim of this study is to investigate the effect of short term ghrelin administration to humans on metabolism.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Subjects

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

About this study

The current study is initiated in order to assess the impact of acute ghrelin administration on insulin resistance measured by a hyperinsulinemic euglycemic clamp. Second, as free fatty acid is the predominant substrate during fasting, we aim to asses the effects of ghrelin on local and systemic lipolysis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

healthy men, age >= 18 yr age < 50 yr, body mass index < 27.5 kg/m2above or equal to 18 yr

Exclusion criteria

any disease, use of prescribed medication, age < 18 yr or >= 50 yr

Treatment and study plan

Ghrelin and saline (as placebo)

Drug

Intravenous infusion

Primary outcomes

Insulin sensitivity

Time frame: End of clamp period

Secondary outcomes

Effects on lipolysis

Time frame: End of basal and end og clamp period

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Registry information

Official study title

Intravenous Ghrelin Infusion Decreases Insulin Sensitivity in Healthy Young Men

Important dates

Study start: 2003
Primary completion: 2003
Study completion: 2003
First posted: Aug 7, 2007
Registry last updated: Sep 9, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed